Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05899816 · ClinicalTrials.gov registry record · Phase 3
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
A Phase 3 study of Atopic Dermatitis and Moderate-to-Severe Atopic Dermatitis, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 221
- Enrollment target
- 20
- Study locations
NCT05899816 is a Phase 3 study of Atopic Dermatitis and Moderate-to-Severe Atopic Dermatitis that has completed, run by Amgen. The registered enrollment target is 221 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT05899816, a Phase 3 study of Atopic Dermatitis and Moderate-to-Severe Atopic Dermatitis, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 221 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of this study are to: * estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus response at Week 24 * estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-meningococcal response at Week 24
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rocatinlimab
Study Locations (20)
California
- Kern Research Inc - Bakersfield
- Hope Clinical Research LLC - Canoga Park
- Doc1 Healthcare Systems - Chino
- 310 Clinical Research - Inglewood
- Chemidox Clinical Trials Incorporated - Lancaster
- Long Beach Research Institute - Long Beach
- University of California Los Angeles - Los Angeles
- Wallace Medical Group Inc - Los Angeles
- West Los Angeles Clinical Trials - Los Angeles
- Northridge Clinical Trials - Northridge
- Havana Research Institute Inc - Pasadena
- Peninsula Research Associates - Rolling Hills Estates
- Integrative Skin Science and Research - Sacramento
- Wake Research Medical Center for Clinical Research - San Diego
- Cura Clinical Research - Sherman Oaks
Arizona
- Affiliated Dermatology - Scottsdale
- Center for Dermatology and Plastic Surgery - Scottsdale
- Scottsdale Clinical Trials - Scottsdale
- Medical Advancement Centers of Arizona - Tempe
Arkansas
- Little Rock Allergy and Asthma Clinical Research Center - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2023-06-07 |
| Est. Completion | 2024-11-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05899816
The ClinicalTrials.gov registry entry for NCT05899816 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (64% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05899816 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05899816 about?
NCT05899816 is a clinical study titled "A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)". The primary objectives of this study are to: * estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus response at Week 24 * estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-meningococcal response at Week 2...
What is the current status of trial NCT05899816?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 221 participants. The study started on 2023-06-07. Estimated completion is 2024-11-14.
What conditions does trial NCT05899816 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Moderate-to-Severe Atopic Dermatitis.
What interventions are being tested in trial NCT05899816?
The interventions under investigation include: Placebo (DRUG), Rocatinlimab (DRUG).
Who is sponsoring clinical trial NCT05899816?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05899816 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.